ANNE SPADE: Open Payments
NPI 1083264048 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$505 in 21 payments from 11 companies in 2025. Trend: 2023 $391 · 2024 $240 · 2025 $505
Food & beverage: $505
| Company | Payments | Amount |
|---|---|---|
| AKEBIA THERAPEUTICS INC | 1 | $108 |
| Calliditas Therapeutics US Inc. | 3 | $75 |
| Novartis Pharmaceuticals Corporation | 2 | $61 |
| Travere Therapeutics, Inc. | 4 | $52 |
| Novo Nordisk Inc | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
Products named: Vafseo, TARPEYO, Fabhalta, Ozempic, FARXIGA, VELPHORO, JARDIANCE, Veltassa.
Industry payments across MO — which companies pay providers there.
